Universiteit Maastricht — Sponsor Intelligence | 8 EU Trials

Filter these 8 trials by condition, phase, country and more.

8 Registered trials

2 Recruiting

3 Completed trials

1 Countries active

8 Unique IMPs

100% Results reported

Phase II

Phase IV

Oversight events:

1 temporary halt across 1 trial

100%

3 of 3 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

Top indications

8 total

Treatments of COVID-19 in primary care in the Netherlands Not authorised

2022-500678-33-00 Phase IV 1 country MONTELUKAST
Microdosing for ADHD and emotion regulation Not authorised

2025-520906-36-00 Phase II 1 country LYSERGIDE
TMSxDCS: Medicinal improvement of brain stimulation for depression. Pending

2025-521166-95-00 Phase II 1 country CYCLOSERINE
MetAddon: Methadone as co-analgesic for patients with metastatic bone pain: a double-blind randomized controlled trial Recruiting

2025-522710-22-00 Phase IV 1 country METHADONE HYDROCHLORIDE; MORPHINE SULFATE
Role of BCAA in glucose homeostasis Recruiting

2023-503424-12-00 Phase IV 1 country SODIUM PHENYLBUTYRATE
Het effect van psilocybine op pijn bij fibromyalgiepatiënten: een multicenter trial Ended

2024-516890-63-00 Phase II 1 country PSILOCYBINE
CoCroS trial Ended

2024-516002-33-01 Phase IV 1 country ADALIMUMAB
Treatments of COVID-19 in primary care in the Netherlands Ended

2022-501559-99-00 Phase IV 1 country MONTELUKAST

Showing 1–8 of 8 trials